Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CASZ1 Is Essential for Skin Epidermal Terminal Differentiation.
Droll SH, Zhang BJ, Levine MC, Xue C, Ho PJ, Bao X. Droll SH, et al. Among authors: ho pj. J Invest Dermatol. 2024 Sep;144(9):2029-2038. doi: 10.1016/j.jid.2024.02.014. Epub 2024 Mar 6. J Invest Dermatol. 2024. PMID: 38458428 Free PMC article.
Non-linear enhancement of ultrafast X-ray diffraction through transient resonances.
Kuschel S, Ho PJ, Al Haddad A, Zimmermann FF, Flueckiger L, Ware MR, Duris J, MacArthur JP, Lutman A, Lin MF, Li X, Nakahara K, Aldrich JW, Walter P, Young L, Bostedt C, Marinelli A, Gorkhover T. Kuschel S, et al. Among authors: ho pj. Nat Commun. 2025 Jan 20;16(1):847. doi: 10.1038/s41467-025-56046-y. Nat Commun. 2025. PMID: 39833149 Free PMC article.
Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More Therapies.
Abadir E, Wayte R, Li W, Gupta S, Yang S, Reaiche E, Debosz K, Anderson E, Favaloro J, Aklilu E, Brown C, Bryant C, Dunkley S, McCulloch D, Larsen S, Rasko JEJ, Vanguru V, Ho PJ. Abadir E, et al. Among authors: ho pj. Transplant Cell Ther. 2025 Jan 6:S2666-6367(25)00002-8. doi: 10.1016/j.jtct.2025.01.001. Online ahead of print. Transplant Cell Ther. 2025. PMID: 39778811
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz SM. Iyer SP, et al. Among authors: ho pj. Lancet Oncol. 2025 Jan;26(1):110-122. doi: 10.1016/S1470-2045(24)00508-4. Epub 2024 Nov 29. Lancet Oncol. 2025. PMID: 39617017 Clinical Trial.
Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.
Lim KJC, Wellard C, Moore E, Ninkovic S, Chng WJ, Spencer A, Mollee P, Hocking J, Ho PJ, Janowski W, Kim K, McCaughan G, Dun K, McQuilten ZK, Chen F, Quach H. Lim KJC, et al. Among authors: ho pj. Clin Lymphoma Myeloma Leuk. 2024 Nov 9:S2152-2650(24)02402-9. doi: 10.1016/j.clml.2024.11.002. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39616008 No abstract available.
224 results